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Abstract Urinary tract infection (UTI) encompasses a vari-
ety of clinical syndromes ranging from mild to life-threatening
conditions. As such, it represents an interesting model for the
development of an analytically based scoring system of disease
severity and/or host response. Here we test the feasibility of this
concept using 1H NMR based metabolomics as the analytical
platform. Using an exhaustively clinically characterized cohort
and taking advantage of the multi-level study design, which
opens possibilities for case–control and longitudinal modeling,
we were able to identify molecular discriminators that charac-
terize UTI patients. Among those discriminators a number (e.g.
acetate, trimethylamine and others) showed association with
the degree of bacterial contamination of urine, whereas others,
such as, for instance, scyllo-inositol and para-aminohippuric
acid, are more likely to be the markers of morbidity.
Keywords Metabolomics  NMR  Data analysis 
Clinical metabolomics  Urinary tract infection
1 Introduction
Despite the progress made to date in understanding the
mechanistic basis of many diseases, medicine is still essen-
tially ‘‘more an art than a science’’ (Woodcock 2007). Spe-
cific and sensitive biological markers are important
contributors to the improved diagnostic methods as well as to
patient care and drug discovery. Advanced ‘‘-omics’’ tech-
nologies, such as genomics, proteomics and metabolomics,
enable identification of such markers (Vaidya and Bonventre
2010). Of our particular interest is metabolomics that focuses
on the analysis of metabolites present in biological fluids.
Metabolites are end-points of all the biochemical processes of
the organism and thus their collection—the metabolome is
the closest approximation of the physiological phenotype and
as such has a great potential for uncovering the biology
underlying diseases and providing valuable markers of
pathology (Lindon and Nicholson 2008; Holmes et al. 2008).
The biological interpretation of results from metabolo-
mics studies is rather complex and still in an early phase of
development (Mendes and Camacho 2005). The human
body is a ‘‘super-organism’’ that unites its own network of
interconnected tissues and organs with multiple colonies
of microorganisms (Nicholson et al. 2005). Interpretation
of changes in concentration of metabolites found in bio-
logical fluids can readily be performed based on the
underlying metabolic pathway; however, it is not always
possible to link the observed change in systemic metabolite
concentrations to a specific tissue or organ (Adourian et al.
2008). Especially in the case of disruption of highly
abundant metabolites, e.g. from energy or amino acid
metabolism, additional information would be required in
order to interpret the data in respect to the tissue of origin.
In addition, a change of such metabolites does not always
improve the knowledge about the underlying cellular
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mechanisms and biology. A way to facilitate the interpre-
tation of clinical metabolomics data is to integrate a
plethora of available clinical parameters and to utilize a
multilevel study design that should provide the opportunity
to access the various levels of biological processes.
One of the examples of a complex and heterogeneous
clinical entity, for which current diagnostic methods are not
straightforward, is urinary tract infection (UTI) (Wilson and
Gaido 2004). Clinical manifestations of UTI can cover the
range from mild cystitis to advanced pyelonephritis potentially
leading to urosepsis and multiple-organ failure. Physical
symptoms may vary from patient to patient and be similar to a
number of other diseases, mainly of infectious origin. Thus, the
presence of bacteria and leucocytes in urine can not be con-
sidered as a sole common denominator for UTI and even if it
was, the criterion for the colony count is variable and anyway
considered insensitive (Johnson 2004). The correct and timely
diagnosis relies on effective joint work of clinicians and
microbiologists (Johnson 2004). All of this explains the con-
siderable interest in providing new, specific and sensitive
markers for UTI and for the uropathogen involved. The focus
of the available metabolomics studies on UTI in the literature
has so far been on the identification of pathogens: in the work
of Gupta et al. a beautiful method with the use of 1H NMR was
proposed (Gupta et al. 2006, 2009; Gupta and Dwivedi 2005).
However, the method is targeted solely to the pathogens,
leaving all host-related questions, such as localization of the
infection within urinary tract and morbidity, unexplored.
In the current study we investigated possibilities of
using urinary metabolic profiles to monitor the health state
of UTI patients, the degree of infection and the recovery
process of UTI patients in the context of febrile, compli-
cated UTI. We used a selection of samples from an
exhaustively characterized cohort, with multiple urine
samples available per individual and with the main path-
ogen identified as Escherichia coli, which is the most
common pathogen for UTI. Samples from a group of age-
and gender- matched UTI symptom-free subjects were
included as control. The longitudinal design allowed
studying various biological processes: not only the differ-
ence between the patients and controls, but also the
recovery process, using each patient as its own control.
2 Materials and methods
2.1 Samples
The study protocol was approved by the ethical committee
of the Leiden University Medical Center and all included
patients gave written informed consent.
Urine samples were collected at the Emergency
Department and Primary Care Department from adult
patients presenting with febrile UTI. The methods have
been described previously (van der Starre et al. 2011; van
Nieuwkoop et al. 2010). The sampling was carried out at
several time points: the first urine samples were collected at
the day of enrolment as baseline samples (t = 0). Clean
midstream-catch urine cultures were obtained and were
analyzed using local standard microbiological methods.
Three-four (t = 4) and 30 days (t = 30) after the day of
enrolment, urine samples of the same patients were col-
lected and new bacterial culture tests were performed
(Supplementary Fig. 1).
For the current study, from a database of 253 subjects
enrolled, 40 subjects, for which urine culture confirmed
E. coli-positive complicated febrile UTI infection that
recovered after antibiotic treatment, were randomly selec-
ted (Supplementary Fig. 1). Samples from age- and gender-
matched subjects with low bacterial culture in urine and
without evidence of inflammatory diseases were used as
controls (Table 1). A number of samples were missing, a
few removed from the analysis due to either insufficient
spectra quality or high glucose content (Supplementary
Fig. 1). In the end the study included four classes of
samples originating from UTI symptom-free (N = 35) at
day 0 (baseline control), UTI patients (N = 32) at day 0
(baseline), UTI patients (N = 29) at day 4 and UTI patients
after recovery from infection (N = 37) at day 30 (Sup-
plementary Fig. 1).
2.2 Sample preparation
Samples were thawed, transferred into 96 deep-well plates
and centrifuged at 3,0009g for 15 min at 4C to remove any
Table 1 Characteristics of the studied patients and controls groups at
baseline (t = 0)
Characteristics UTI patients Controls P value
N = 40 N = 40
Age, years, median (sd) 59 (14.6) 58 (17.9) 0.9
Female, N (%) 22 (55) 22 (55) 1
Smoking, N (%) 5 (12) 5 (12) 1
Co-morbidity, N (%)
Urinary tract disorder 4 (10) 4 (10) 1
Malignancy 4 (10) 1 (3) 0.17
Heart failure 5 (13) 3 (8) 0.46
Renal insufficiency 1 (4) 0 (0) 0.13
Diabetes mellitus 6 (15) 2 (5) 0.14
Immunocompromised 1 (3) 1 (3) 1
Urine dipstick results
Nitrite 26/37 (75)a 0/37 (0)a \0.001
Leucocyte esterase 35/37 (95)a 5/37 (14)a \0.001
a 3 missing values
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precipitate. For sample preparation 520 ll urine were mixed
with 60 ll of pH 7.0 phosphate buffer (1.5 M) in 100%
D2O containing 4 mM sodium 3-trimethylsilyl-tetra-
deuteriopropionate (TSP) and 2 mM NaN3 in a 96 deep-well
plate using a Gilson 215 liquid handler controlled by a Bruker
Sample Track LIMS system (Bruker BioSpin, Karlsruhe,
Germany).
2.3 NMR experiments and processing
1H NMR data were collected using a Bruker 600 MHz
AVANCE II spectrometer equipped with a 5 mm TCI cryo-
genic probe head and a z-gradient system; a Bruker BEST
(Bruker Efficient Sample Transfer) system was used in com-
bination with a 120 ll CryoFIT
TM
flow insert for sample
transfer. One-dimensional (1D) 1H NMR spectra were recor-
ded at 300 K using the first increment of a NOESY pulse
sequence (Kumar et al. 1980) with presaturation (cB1 =
50 Hz) during a relaxation delay of 4 s and a mixing time of
10 ms for efficient water suppression(Price 1999). Eight scans
of 65,536 points covering 12,335 Hz were recorded and zero
filled to 65,536 complex points prior to Fourier transformation,
an exponential window function was applied with a line-
broadening factor of 1.0 Hz. The spectra were manually phase
and baseline corrected and automatically referenced to the
internal standard (TSP = 0.0 ppm). Phase offset artifacts of
the residual water resonance were manually corrected using a
polynomial of degree 5 least square fit filtering of the free
induction decay (Coron et al. 2001). In order to monitor proper
filling of the NMR flow cell and for quality control 1D gradient
profiles (Vanzijl et al. 1994) along the z axis were recorded for
each sample prior and post data acquisition. Duration of 90
pulses were automatically calibrated for each individual
sample using a homonuclear-gated nutation experiment (Wu
and Otting 2005) on the locked and shimmed samples after
automatic tuning and matching of the probe head.
2.4 Statistical analysis
Each spectrum was integrated (binned) using 0.014 ppm
integral regions between 10 and 1 ppm, the residual water
and urea region between 6 and 4.5 ppm was excluded,
resulting in 550 data points used for the analysis. To account
for any difference in concentration between the samples,
each spectrum was normalized to a total area of 1. Absolute
values were log-transformed. All pre-processing was done
using in-house developed routines in R statistical environ-
ment (http://www.r-project.org/). Variables were centered
and unit variance scaled prior to statistical analysis in
SIMCA-P? (version 12.0; Umetrics, Sweden) software
package. For initial analysis and outlier detection, principal
component analysis (PCA) was performed using 10 com-
ponents. After the initial PCA analysis the following regions
corresponding to paracetamol and its metabolites were
excluded from the analysis: 7.5–6.75, 3.95–3.8, 3.7–3.45,
2.2–2.14 and 1.84–1.88 ppm according to (Bales et al.
1985). For partial least squares-discriminant analysis (PLS-
DA) (Nocairi et al. 2005) samples were categorized based
on classes as defined by the study design. PLS model was
built using 5 categories according to logarithm of bacterial
count as a Y variable. Statistical models from supervised
multivariate data analysis were validated by random per-
mutation of the response variable and comparison of the
goodness of fit (R2Y and Q2) (Westerhuis et al. 2008;
Lindgren et al. 1996). For random permutation tests 100
models were calculated and the goodness of fit was com-
pared with the original model in a validation plot. Spectral
regions responsible for the separation between classes in
supervised models were identified based on the Variable
Influence on Projection (VIP) values, which correspond to
the importance of the variables (bins) for the model. The
variables with a VIP value larger than 1.8 were considered
significant and used for further analysis and identification of
the responsible peak(s) within the spectrum. Prediction of
class membership of samples by PLS-DA model was based
on the predicted Y variable with the cut-off of 0.5.
For multilevel component analysis using an in-house
developed script in R as described by Jansen et al. (2005).
data were not log-transformed. To assess the predictive
ability of multilevel PLS-DA in each cross-validation
round all the samples, belonging to two random individuals
were taken out.
Univariate tests were performed to assess the statistical
significance of the spectroscopic regions found using multi-
variate analysis: unpaired t-test was performed for the regions
found as discriminating between UTI patients and controls by
PLS-DA; ANOVA was performed on the regions that
showed association with bacterial count in PLS; paired t test
was carried out on the regions identified in multilevel anal-
ysis. All the corresponding P values were adjusted for mul-
tiple testing using Benjamini–Hochberg correction.
2.5 Identification of compounds of interest
Annotation of identified peaks was performed based on
reference spectra from the Bruker Bioref database and
in-house reference data. Confident identification was
facilitated by the use of Statistical Total Correlation
SpectroscopY method (Cloarec et al. 2005).
2.6 Quantification of paracetamol and differential
metabolites
Quantification was performed by deconvolution and sub-
sequent integration of resonances, corresponding to the
compounds of interest, using an in-house developed
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automation routine. Paracetamol–glucuronide was quanti-
fied based on the resonance at 5.10 ppm (d, 7.1 Hz); for
other compounds the signal with high intensity and low
degree of overlapping was chosen for quantification. The
absolute concentrations were calculated based on internal
reference TSP. Values were not corrected for differential
attenuation of the signals caused by relaxation during the
mixing time and rapid-pulsing saturation effects.
3 Results
The initial PCA on baseline samples revealed a trend in
separation between UTI patients and controls in the scores
plot of the first two principal components as shown in
Fig. 1a. The loadings plot of this model was dominated by
the spectral regions that belonged to one of the most
commonly used over-the-counter analgesic, paracetamol
(Supplementary Fig. 2). The absolute concentration of
paracetamol-glucuronide was used to stratify samples in
the PCA plot: the direction of increase of paracetamol-
glucuronide was found to match the direction of controls-
patients separation (Fig. 1b). As paracetamol is not an
infection or morbidity marker, the further analysis was
performed after the exclusion of the regions corresponding
to the drug and its metabolites.
The PCA analysis of the baseline samples after the
removal of spectral regions of paracetamol and its metab-
olites did not show separation between UTI patients and
controls within the scores plot of the first two principal
components; however, a clear trend was identified along
the third principal component (Fig. 2), which means that
inter-individual variability is to a certain extent more
prominent than the disease effect. No outliers were detec-
ted based on distance to the model (DModX). The samples
with other conditions than UTI (as defined in Table 2) did
not exhibit any clustering in PCA scores plot.
In the next step a supervised PLS-DA model was built
for t = 0 using UTI/controls as a response variable. In the
scores plot of the resulting model the two groups were well
separated (Fig. 3). Cumulative explained variance (R2Y) of
0.88 and cross validated predictive fraction (Q2) of 0.63
were calculated for the model; the model validation plot
showed intercepts of the R2Y and Q2 regression lines
with the vertical axis at 0.63 and -0.11, respectively,
indicating a valid model. Molecular discriminators were






































Fig. 1 PCA scores plot of 1H NMR data from controls and UTI
patients urine samples at baseline, first two principal components
covering 14.5 and 10.2% of variation respectively. a Colored
according to controls (square) and UTI patients (circle). b Colored
according to the logarithm of absolute concentration of paracetamol–
glucuronide (Color figure online)
Fig. 2 PCA scores plots of 1H NMR data from controls (black) and
UTI patients (red) urine samples at baseline after removal of the
regions corresponding to paracetamol and its metabolites. First
principal component covers 11.7%, second 11.2% and third 9.8% of
variation (Color figure online)
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corresponding VIP. A list of those regions, along with the
p-values based on t-test for the quantified compounds, the
direction of change and identities of the corresponding
metabolites are summarized in Table 2.
The advantage of PLS-based models is that they can
easily be used to predict the class membership of new
samples. Data of the UTI patients at t = 4 were pre-
dicted using the two-class PLS-DA model that was built
as described above. Of a total of 29 urine samples
included in the prediction set, 19 (65.5%) were classified
as controls, whereas 10 (34.5%) samples were classified
as UTI (Fig. 4). Besides using data from the 4-days time
point as prediction set, we also performed a separate
analysis for the 30-days time point (Fig. 4). In this case,
out of 37 samples collected, 32 (86.5%) were attributed
to the group of controls and 5 (13.5%) were categorized
as UTI.
An important parameter characterizing UTI patients is
the number of bacteria in urine; however, bacteria can also
be present in urine of the individuals, who do not exhibit
any symptoms of UTI (Lin and Fajardo 2008). We built a
PLS regression model from NMR data of urine at baseline
using the result of bacterial culture as response variable.
Since bacterial count and UTI classification do not fully
correlate we expected to obtain a slightly different model
as compared to the model built based on UTI classification
for this timepoint. Using 2 components a cumulative
R2Y = 0.78 and Q2 = 0.44 were obtained and model
Table 2 Spectroscopic regions that appear as influential in various statistical models and the statistical significance of the corresponding
univariate tests based on the quantified corresponding peaks
Identity ChemSpider
IDs






t test Change ANOVA
P value
Change Paired Change
P value t test
P value
1-Methylnicotinamide 10628510 9.284, 9.271, 8.971, 4.484 9.00E-07 ; 2.00E-05 ;
Acetic acid 170 1.934, 1.921 7.00E-08 : 2.00E-07 :
Acylcarnitine NA 3.189 0.004 :
Citric acid 29081 2.562, 2.534 9.00E-05 ;
Creatinine 568 4.075, 3.066, 3.052 0.3 ;
Furoylglycine 20474156 7.703, 7.689 0.15 :
Glycolic acid derivative NA 3.953 0.55 ; 0.56 ; 0.55 :
Hippuric acid 451 7.853, 7.662, 7.648, 7.580,
3.966, 8.548, 8.534
0.001 ; 0.001 ;
Lactic acid 96860 1.334 0.0008 : 0.0002 :
Para-aminohippuric acid 2063 7.757 0.055 :
Scyllo-inositol 23975912 3.325 0.1 :
Taurine 1091 3.448, 3.434, 3.421, 3.257 1.00E-03 : 0.08 : 2.00E-07 ;
Trigonelline 5369 8.698, 4.443 0.09 :
Trimethylamine 1114 2.889 4.00E-06 : 0.0001 : 0.0001
Unknown 1 NA 7.962 0.01 :
Unknown 2 NA 7.743 0.015 :
Unknown 3 NA 7.512 0.0006 :
Unknown 4 NA 6.68 4.00E-05 :
Unknown 5 NA 6.503 0.065 :
Unknown 6 NA 3.162 0.05 ;
a Chemical shift corresponding to the center of the bin region
b Two-group t test for the healthy controls and UTI patients at baseline; : corresponds to intensity of the region being higher in UTI patients
compared to controls, ; means that region intensity is lower in UTI patients compared to controls
c ANOVA analysis for the number of bacteria present in urine; direction corresponds to the correlation to the number of bacteria: : corresponds
to the raise of the region intensity with the increase of the number of bacteria, ; to the decrease of the region intensity with the increase of the
number of bacteria
d Paired t test for the UTI patients at baseline and 30 days; : direction of change corresponds to intensity of the region being higher at 30 days
compared to baseline, ; means that region intensity is lower at 30 days compared to baseline
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validation showed intercepts of the R2Y and Q2Y regres-
sion lines with the vertical axis at 0.63 and -0.12,
respectively, in the model validation plot. As can be seen
from the PLS scores plot (Fig. 5) the samples with the
highest bacteria concentration in urine were very distinct
from the rest forming a separate cluster, whereas the rest of
the samples were overlapping. The spectral regions
responsible for the correlation of the 1H NMR data and
bacterial count were chosen on the basis of the corre-
sponding VIP. A list of those regions, along with the
P values derived from ANOVA based on the quantified
compounds, the direction of change and identities of the
corresponding metabolites are summarized in Table 2.
To better understand the process of patient recovery and
to find the spectroscopic regions that correlate with this
process, we took advantage of the longitudinal study
design. One of the statistical methods suitable for such
analysis is multilevel component analysis that separates
variation present in the data into two levels: between-
individual and within-individual. We performed this anal-
ysis on the 29 patients for which both the data from the
baseline and from the 30-days time point were available
and concentrated on the within-individual information.
This should best reflect the recovery from the baseline,
when patients are diagnosed as infected, to 30 days, when
they are considered UTI symptom-free. PCA scores plot of

























Fig. 3 Cross-validated PLS-DA scores plot of urine 1H NMR spectra
of controls (square) and UTI patients at baseline (circle),

























UTI patients t=0 UTI patients t=4 UTI patients t=30
Fig. 4 Predicted response value
for two-class PLS-DA model
based on controls (black bars)
and UTI patients (red bars) at
baseline: blue bars are the t = 4
and t = 30 classified as
controls, grey are the t = 4 and
t = 30 samples classified as





























Fig. 5 Scores plot of the PLS model of urine 1H NMR spectra at
baseline versus the number of bacteria (CFU/ml) found in urine
(R2Y = 0.78, Q2 = 0.44). Colored by the number of bacteria (Color
figure online)
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14.8% of the variation, respectively, showed good separa-
tion between baseline and t = 30 time points (data not
shown). The PLS-DA model of this data had high quality
parameters (R2Y = 0.98, Q2 = 0.78 for four components),
performs significantly better then random models
(P \ 10-15) and perfectly separated the two time points
(data not shown). The NMR spectral regions responsible
for the separation between baseline and the t = 30 time
point were identified based on VIP values. The underlying
metabolites as well as the p-values from paired t-test based
on the quantified compounds and the direction of change
are summarized in Table 2.
To summarize, taking advantage of our study design we
built several statistical models, which allowed getting a
broader view of metabolic features associated with UTI,
than the traditional ‘‘case–control’’ design.
4 Discussion
UTI, as many other disorders, represents a complex clinical
entity, for which diagnostics is not straightforward and
based on consensus criteria (Wilson and Gaido 2004).
Thus, unlike in animal experiments, in clinical research
assigning people to certain groups is not always uncondi-
tional. The diagnosis of a disease can be ambiguous and
defining the healthy group can be complicated by that there
is no clear definition of ‘‘healthy’’. Consequently, it may be
very advantageous to supplement a traditional ‘‘case–con-
trol’’ design with a more complex study design and the use
of additional clinical data. When used without extra
information, ‘‘case–control’’ analysis might even be mis-
leading. For example, the separation of the control and UTI
groups was seen in the first two principal components of
PCA; however, this discrimination was not disease-related,
but the result of patients taking the antipyretic and anal-
gesic drug paracetamol. An analysis strategy for such type
of data is to identify all of the spectroscopic regions that
contain signals from drug-related compounds and to
exclude them prior to further analysis. However, it is not
feasible to account for the whole range of the medication
used and, more importantly within the context of clinical
metabolomics studies in general, to account for drug-rela-
ted shifts in metabolism, especially in the case of long-term
treatment regimes of chronic conditions. It is essential to
consider such effects when developing the study design in
order to minimize or control such influences.
Samples from 4 days after admission, when the patients
were still under therapy, but on the way to recovery, were
used to check if the modeled differences were related to the
effect of medication or not. The fact that the majority of
those samples were classified as healthy by the model built
on baseline samples is an indication that the model is not
reflecting therapy/drug intake, but is indeed related to the
clinical difference between the groups.
The samples from the 30-days time point, when UTI
patients were symptom-free, could also be used to gain
additional information on the performance of the model as
well as to get insight into the underlying biology. When
predicted using the PLS-DA model built on the baseline
UTI infected and UTI symptom-free samples, most of the
30-days samples (86.5%) were projected to the control
group. Those few, which were still predicted as infected
UTI patients, may have another condition (as we do not
know at this point how specific our model is) or have
asymptomatic UTI. On the other hand, they can be healthy
and be false positives, as the predictive ability of our
model, estimated by cross-validation was 63%. There was
neither a consistent pattern of metabolites that would
describe the prediction of 30-days samples as infected, nor
common complication/co-morbidity between those sam-
ples, which makes it difficult to suppose the reason for the
misprediction. Despite that, considering the prediction of
30-days samples as an independent statistical test for our
model, it gives very satisfactory results.
Pair-wise analysis for baseline and 30-days samples
from the same individuals was conducted in order to
monitor the recovery process. It revealed a number of
classifiers and improved their statistical significance. The
identified metabolites overlapped with the compounds
from the model discriminating healthy and UTI subjects,
however a few of them were unique (para-aminohippuric
acid, scyllo-inositol and a few unidentified compounds).
Besides the multilevel design, the advantage of the
current study was the exhaustive clinical characterization
of the patients. Among the variety of clinical parameters
available, the number of bacteria in urine was of specific
importance. We performed regression-based analysis of the
relation between the 1H NMR data and the bacterial load in
urine as determined by bacterial culture. The classifiers that
emerged from this analysis were to a certain extent over-
lapping with the classifiers derived from the discriminative
model on baseline samples. This was no surprise, since
UTI is generally characterized by the presence of bacteria
in urine.
Straightforward assignment of classifiers from each
model to the intracellular biochemical pathways will not
improve the understanding of UTI. We tried to use the
information available from the different statistical models
jointly in order to enrich the biological interpretation.
When comparing the lists of discriminators obtained from
the different models (discriminating UTI patients from
controls, modeling the recovery process and modeling the
data against the degree of bacterial contamination of urine)
it is evident that there is a large overlap which makes
biological interpretation of the results feasible. For
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instance, some of the overlapping metabolites were already
known from the literature to be related to the bacterial
contamination of urine: acetate, lactate and trimethylamine
(Gupta et al. 2009). Others, if they were found only in the
comparative analysis of the two groups, could be attributed
based on previous studies to certain phenomena. Hippuric
acid, for example, is often associated with the gut micro-
flora (Swann et al. 2009) and taurine with liver toxicity
(Nicholson et al. 1999). However, our findings suggest that
they are also associated with the bacterial contamination of
urine, which obviously does not mean that they are not
related to the mentioned physiological processes as well,
but that a complex network of interconnected factors is
involved. The metabolites that appear to be related to the
recovery process might be considered as potential mor-
bidity markers. One of them, para-aminohippuric acid, is a
well-established diagnostic marker for renal plasma flow
and glomerular filtration (Reubi 1953). The recovery from
the complicated, tissue-invasive UTI is associated with the
resumption of the kidneys’ function, so the positive change
in para-aminohippuric acid corroborates our assumption
that some of the markers discovered in the paired analysis
are the markers of morbidity.
Despite the promising discriminatory and predictive
abilities of the statistical models, described above, their
real clinical utility would need careful examination. As a
first attempt we restricted ourselves to the case of E. coli as
the main pathogen of UTI. Currently we are planning to
investigate if our models will hold when samples with
other pathogens are added. Besides that, the specificities of
the models with regard to other diseases of both infectious
and non-infectious origin have to be assessed.
5 Conclusions
In the current paper we used a metabolomics approach to
profile UTI, which is on the one hand one of the most
common infectious diseases among the adults, and on the
other hand a disease that still lacks markers of morbidity.
Using 1H NMR profiles of urine we generated various
statistical models: (a) discriminating UTI patients and
control subjects, (b) following the recovery process of UTI
patients and (c) associating urine metabolic content with
bacterial contamination. The discriminative model was
able to classify most of the independent samples correctly
according to their diagnosis, which indicates its high pre-
dictive ability. Comparing the sets of molecules derived
from different analyses, we concluded that some of the
compounds (e.g. trimethylamine and acetate) can be
attributed to the effect of bacterial contamination of urine;
others (e.g. para-aminohippuric acid, scyllo-inositol) can
be considered markers of morbidity.
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